drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A therapeutic mRNA vaccine encoding hepatitis B virus (HBV) antigens, administered intramuscularly with dose escalation (starting at 20 µg), weekly for 4 doses followed by a 1‑month booster. The mRNA is taken up by antigen-presenting cells (especially dendritic cells), translated into HBV antigens, and presented via MHC I/II to prime HBV-specific CD8+ and CD4+ T-cell responses (and potentially antibody responses) aimed at eliminating HBV antigen–expressing hepatocellular carcinoma cells.
nci_thesaurus_concept_id
C200119
nci_thesaurus_definition
A vaccine consisting of a mRNA delivery vector encapsulating messenger RNA (mRNA) encoding an unspecified antigen of hepatitis B virus (HBV), with potential immunomodulating and antineoplastic activities. Upon administration of the HBV mRNA vaccine, the mRNA delivery vector releases HBV mRNA into the cells. The mRNA is then translated by the cellular protein translation machinery to produce the HBV antigen. This results in the induction of antigen-specific CD8+ and CD4+ T-cell responses against the HBV antigen. HBV infection is present in many hepatocellular carcinoma patients.
drug_mesh_term
RNA Vaccines
drug_category
mRNA VACCINE
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Encapsulated mRNA encoding HBV antigens is taken up by antigen-presenting cells, translated into HBV proteins, and presented via MHC I and II to induce HBV-specific CD8+ and CD4+ T-cell responses (and antibodies), promoting immune-mediated elimination of HBV antigen-expressing hepatocellular carcinoma cells.
drug_name
HBV mRNA vaccine
nct_id_drug_ref
NCT05738447